Features | VJHemOnc

FDA approve ibrutinib and rituximab combination for CLL

Following positive results gleaned from the E1912 trial (NCT02048813), the U.S. Food and Drug Administration (FDA) has expanded the indication…

NK-cell therapy IND application for AML & MDS

Kiadis Pharma have filed the first investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for…

Venetoclax-based regimens for NPM1-mutated AML

The molecular chaperone nucleophosmin-1 (NPM1) is involved with cellular epigenetic regulation through nuclear-cytoplasmic protein shuttling, ribosomal assembly, and the maintenance…

The impact of genetic mutations on the performance of anti-CD19 CAR T-cells in CLL

Chimeric antigen receptor T-cell (CAR-T) therapies have proven particularly successful in hematological malignancies. However, CAR T-cells still underperform when used…

Radioimmunotherapy agent improves progression-free survival of NHL patients in real-world setting

A study presented during the 2020 American Society of Clinical Oncology and Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium,…

Begelomab for steroid-resistant acute GvHD

Hematopoietic stem cell transplantation (HSCT) is an incredibly powerful tool in the treatment of hematological malignancies. Testament to this is…

Positive top-line results for pivotal phase III FLASH trial in CTCL

The treatment options for cutaneous T-cell lymphoma (CTCL) are currently limited, with research ongoing in several clinical trials. SGX301 (synthetic…

ASH resources now available for clinicians and researchers during COVID-19 pandemic

In response to the ongoing COVID-19 pandemic, The American Society of Hematology (ASH) have launched a webpage (https://www.hematology.org/covid-19) containing resources…